Dhanji Popatbhai Rajani

Dr. Dhanji Popatbhai Rajani

Microcare Laboratory

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
NPNirav Pandya
Nirav Pandya
YCYasemin Cag
Yasemin Cag
NPNenad Pandak
Nenad Pandak
APAbdullah Umut Pekok
Abdullah Umut Pekok
APAruna Poojary
Aruna Poojary
HEHakan Erdem
Hakan Erdem
Background:Candida auris has emerged globally as a multi-drug resistant yeast and is commonly associated with nosocomial outbreaks in ICUs. Methods: We conducted a retrospective observational multicentre study to determine the epidemiology of C. auris infections, its management strategies, patient outcomes, and infection prevention and control practices across 10 centres from five countries. Results: Significant risk factors for C. auris infection include the age group of 61–70 years (39%), recent history of ICU admission (63%), diabetes (63%), renal failure (52%), presence of CVC (91%) and previous history of antibiotic treatment (96%). C. auris was commonly isolated from blood (76%). Echinocandins were the most sensitive drugs. Most common antifungals used for treatment were caspofungin (40%), anidulafungin (28%) and micafungin (15%). The median duration of treatment was 20 days. Source removal was conductedin 74% patients. All-cause crude mortality rate after 30 days was 37%. Antifungal therapy was associated with a reduction in mortality (OR:0.27) and so was source removal (OR:0.74). Contact isolation precautions were followed in 87% patients. Conclusions:C. auris infection carries a high risk for associated mortality. The organism is mainly resistant to most azoles and even amphotericin-B. Targeted antifungal therapy, mainly an echinocandin, and source control are the prominent therapeutic approaches.

17 May 2023 in Research on Chemical Intermediates
Verified
Journal Article
Closed access
PDF file
JMJaydeep A. Mokariya
Jaydeep A. Mokariya
RPReena C. Patel
Reena C. Patel
DRDhanji Popatbhai Rajani
Dhanji Popatbhai Rajani
MPManish P. Patel
Manish P. Patel

25 October 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
Vinay SainiVinay Saini
Vinay Saini
DMDulce Mata-Espinosa
Dulce Mata-Espinosa
APAlok Pandey
Alok Pandey
DDDR VIKAS DIGHE
DR VIKAS DIGHE
JBJorge Alberto Barrios-Payán
Jorge Alberto Barrios-Payán
RSRohit Srivastava
Rohit Srivastava
Ursolic acid (UA) and oleanolic acid (OA) are hydrophobic triterpenoid isomers with demonstrated anti-mycobacterial (Mtb) and immune-regulatory properties, although their poor solubility limits clinical use. We report the development of solid lipid microparticles (SLMs) as delivery vehicles for UA and OA and evaluate their anti-Mtb efficacy in vitro and in vivo, as well as their acute toxicity. SLMs measured 0.7–0.89 µM in size, with complete in vitro release of OA and UA at 40 and 32 h, respectively. The minimum inhibitory concentration (MIC) of SLMs loaded with OA and UA was 40 µg/mL SLMs + 20 µg/mL OA + 20 µg/mL UA for drug-sensitive Mtb and 80 µg/mL SLMs + 40 µg/mL OA + 40 µg/mL UA for multidrug-resistant (MDR) Mtb. These SLMs showed an efficient reduction in Mtb burden in infected alveolar macrophages. In a murine model of late-stage progressive MDR-TB, aerosolized delivery of SLMs containing OA and UA via a metered-dose inhaler significantly reduced pulmonary bacterial loads and extended survival. In vivo, acute toxicity studies revealed no mortality or signs of toxicity. These findings demonstrate that SLMs are an optimal delivery system for terpenoids, providing potent in vitro and in vivo anti-TB activity with an excellent safety profile.